• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Aug. 9

HYDERABAD-based Natco Pharma Ltd has announced the launch of a drug to treat prostate cancer in the 140-mg capsules form under the brand `X-trant' (estramustine).

In a press release here on Monday, Natco Pharma said X-trant was helpful in the palliative treatment of of prostate carcinoma.

Besides reducing the intensity of pain, X-trant also acts as an anti-tumour agent.

According to the company, the drug's usage will improve performance status of patients suffering from prostate cancer.

The medicine is also useful for patients with limited bone marrow reserve.

Available till now only through the import channel, X-trant will ensure the drug's availability at an affordable price of Rs 13,500 per bottle of 100 capsules, the Natco release said.

More Stories on : Announcements | New Products & Services | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ocimum announces free bioinfo service

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line